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Cardio–renal interactions are com-
mon in acute decompensated heart 
failure (ADHF). Renal insufﬁciency
on presentation, or worsening renal function 
during treatment, can lead to inadequate 
decongestion, progressive decreasing renal 
function, and adverse outcomes (1–3). As  a
result, accurate measurement of renal function is 
paramount for accurate diagnosis and treatment. 
Renal function has classically been quantiﬁed by 
endogenous markers of glomerular ﬁltration rate, like 
serum creatinine and, more recently, cystatin C (4,5). 
Both serum creatinine and cystatin C are pro-gnostic 
for adverse outcomes in both acute and chronic heart 
failure, yet these markers capture little information 
about renal tubular injury in heart failure (6–9).
Kidney injury molecule (KIM)-1 is an epithelial cell 
adhesion glycoprotein that is up-regulated in the 
proximal tubule epithelial cells and modulates the 
regeneration and repair of a post-ischemic kidney 
injury (10,11). Urinary KIM-1 may distinguish acute 
tubular necrosis from other forms of acute renal injury 
or chronic renal insufﬁciency (12,13).
Urinary KIM-1 levels have been suggested as a 
valid biomarker of tubular injury in both acute and 
chronic heart failure, where renal dysfunction is 
common (14). Urinary KIM-1 levels are increased in 
heart failure patients, and often parallel with clin-
ical severity; therefore, they may predict cardiorenal 
syndrome, and may be associated with long-term 
outcomes in chronic heart failure (15–18). However, 
prospective measurement of plasma KIM-1 levels 
in ADHF, as well as evaluating their response to 
medical therapy and their impact on clinical out-
comes, has not been well-established. Because uri-
nary KIM-1 and plasma KIM-1 levels correlate, we 
hypothesize that plasma KIM-1 will show similar 
associations (19).
The ASCEND-HF (Acute Study of Clinical Eff-
ectiveness of Nesiritide in Decompensated Heart 
Failure) biomarker substudy provides a unique op-
portunity to answer these questions (20). We aimed to 
characterize the relationship of KIM-1 levels with 
other indices of renal function and determine their 
association with short-term renal outcomes. We also 
sought to determine the impact of nesiritide on serial 
KIM-1 levels, as well as its impact on intermediate- and
long-term clinical outcomes during and after 
hospi-talization for ADHF.
METHODS
STUDY  POPULATION.  The ASCEND-HF trial was a 
multicenter, randomized, double-blind, placebo-
controlled trial that assessed the effects of nesiritide, a 
recombinant B-type natriuretic peptide with vaso-
dilating properties, in patients hospitalized with ADHF. 
Patients were excluded if there was clinical evidence 
for acute coronary syndrome or baseline cardiac 
troponin >5 the upper reference limit, as measured 
by the local clinical laboratory. The design and primary 
results of ASCEND-HF have been reported previously 
(20,21). Of the  7,411 pa-tients randomly assigned, 
904 were enrolled in the biomarker substudy. These 
subjects had serial venous blood sampling at baseline, 
at 48 to 72 h after therapy initiation, and at a 30-day 
follow-up visit (6,22). Blood samples were collected in 
ethylenediaminetetraacetic acid–plasma, immedi-ately 
centrifuged and stored at -80F for subsequent analysis 
at a core laboratory.
KIM-1  MEASUREMENT.  Circulating plasma KIM-1 levels 
were determined with single molecule count-ing 
immunoassay technology, which has been des-cribed 
previously (23). Brieﬂy, KIM-1 levels in 50-ml plasma 
samples were quantiﬁed using a plate-based sandwich 
immunoassay (capture antibody: Catalog #AF1750 
[R&D Systems, Minneapolis, Minnesota] coated to a 
96-well polystyrene assay plate; detection antibody: 
Alexa-ﬂuor 647-labeled antibody Catalog #AF1750 
[R&D Systems]; standard curve: KIM-1 ana-lyte Catalog 
#1750-TM [R&D Systems]). At the completion of the 
assay, single molecules of detec-tion antibody were 
counted on the Erenna System (Singulex, Alameda, 
California). The reporting range spanned 2 to 1,000 pg/
ml, with an interassay coef-ﬁcient of variation ranging 
from 9% to 15%. Samples reporting results >1,000 pg/
ml,  were diluted 1:10  and retested to obtain a 
result within the assay reporting range.
CLINICAL  ENDPOINTS.  The co-primary endpoints 
from the ASCEND-HF trial were dyspnea improve-
ment (via 7-point Likert scale) at 6 to 24 h and 
the composite endpoint of death or hospitalization
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TABLE 1 Baseline Characteristics 
Basollne KN•1 (pg/mO 
Total 
(n 874) <1783 278.3-526.7 >526.7  pVatue• 
6 7  (55 78) 62 (48 76/ 71 (59 80)  67 (57 78) < 0 . 0 0 0 I  
31.6 27.8 30.1 37.1 O.Ol6 
67.7 65.3 70.9 68.7 
4 6 . 0  28.5 44.2 65 .0 
0.37
< 0 . 0 0 0
I125 (111 140) 123 (110 138) 122 (111 138) 128 (115 143) 
7 9  (70 89)  82 (71 92) 77 (68 87) 77 (67 8 8 )  
41.4 35.7 46.2 4 4 . 0  
78.2 75.6 77.1 82.1 
O.Ol9 
0 .0003 
0 . 0 4 4 
0 .056
2 4  (17 35) 21 (15 28) 25 (18 35) 2 9  (21 43) 
1.3(1.031.7) 1.2 (1.0 1.44) 1 3  (1.04 1.7) 1 5  (1.12 2.0) 
139 (137 141) 139 (136 141) 139 (137 141) 139 (136 141) 
< 0 . 0 0 0 I 
< 0 . 0 0 0 I 
0.73
5,773 (2,98111,579) 4,442 ( 2,431 9,195) 6,399 ( 3,381 12,358) 7,011 (3,226 12,757) <0 . 0 0 0 I  
2 6  (20 40)  25 (17 35) 2 9  (20 4 0 )  30 (20 45) 0 .0005 
Age (yrs) 
Sex (female) 
Race (white) 
Diabetes mellitus 
Systolic BP (nm Hg) 
Heart rate (beats/min) Atrial 
fibrillation Hypertension 
BUN (mg/dO 
Creatinine (mg/dO 
Sodium (mmol/0 
NT proBNP (pg/mO (n 795) 
LVEF 
cardiac troponin I (pg/ml) 
16.4 (9.2 31.6) 14.6 (8.1 28.1) 17.8 (10.0 31.9) 17 3 (9.5 36.2) 0 . 09  
Time from presentation to randomization (h) 17 .7 (8.1 22.6) 18.2 (9.1 22.0) 16.2 (7.2 22.5) 17 .9 (7 3 23.1) 0 .99 
lschemic etiology 60 .0  50.2 66 .4 63.9 0 .0007 
75.0 73.5 74.7 77.0 0.34 
64.3 64 .6 68.2 60.1 0.26 
Beta blockers 
ACEi or ARB 
MRA 24.2 28.2 2 4 3  20.3 0 .026 
values are median (Ql to Q3) or n (%). •p value from te<t of trend (Codlrane-Annitage trend te<t and Jondcheere-Terpstra trend tests). 
ACEl angiot..,,;,.a,nverting OflZ)ffll! inhl>itor; ARB · iotensin r  blod<B; BP blood prt!SS<Jrt!; BUN blood urea nitrogen; KIM kidney;...-, IT'Olewle; 
LVEF left ventriwlar ejection fraction; MRA mineralooortiooid rea,ptor antagonist; NT1)l'OBNP N-tenninal prohorrra,e brain natriuretic peptide. 
for recurrent heart failure within 30 days of ran· 
domization. Dyspnea response was analyzed as a 
dichotomous variable identifying those in whom 
dyspnea had moderately or markedly improved 6 to 
24 h after being assigned randomly. Death and 
worsening heart failure were assessed together as 
a composite secondary endpoint and all events 
were adjudicated through 180 days. 
ST A Tl STI CAL ANALYSE s. Baseline characteristics 
and renal outcomes were presented as median (inter-
quartile range [IQRJ) for continuous variables and as 
percentage for categorical variables. The Jonckheere-
Terpstra and Cochran-Armitage trend tests were used 
to assess the significance of a trend across increasing 
tertiles of KIM·l for continuous and categorical vari· 
ables, respectively. Double-sided p values 0.05 were 
considered significant. Circulating KIM·l levels were 
compared between patients randomly assigned to 
placebo or nesiritide via the Wilcoxon rank-sum 
test. Nonparametric linear correlates of other renal 
biomarkers to KIM·l levels were presented as 
Spearman correlation coefficients (p). The association 
between KIM·l and intermediate outcomes was per-
formed via logistic regression analyses for improve-
ment in dyspnea at 6 and 24 h, and death or worsening 
heart failure in the hospital. After observing no trends 
with time for the Schoenfeld residuals, the association 
ofKIM·l and long-term outcomes was performed via 
Cox proportional hazards models for the endpoints of 
30-day mortality, 30-day mortality or worsening heart 
failure, and 180-day mortality. For multivariable 
analyses, we adjusted for covariates that have been 
identified for the overall ASCEND-HF study popu-
lation, as described previously (6,22). The Kaplan-
Meier method was used to compare 180-day mor· 
tality across groups. Differences across tertiles 
of KIM·l levels and across strata of median KIM·l 
and median cystatin C were determined by the log-
rank test. All statistical analyses were performed 
using SAS software, version 9.3 (SAS Institute, Cary, 
North Carolina). 
TABLE 2 Impact of Neslrltlde Therapy on Serial Changes In KIM·1 Levels 
"'-ho  Neslrltlde 
KIM•1 L.,,.ls (pg/mO (n 436) (n 438) 
BaseLine 366  (234 to 622) 388 (240 to 649) 
4 8  72 h 3 6 8  (215 to 608 )  395 (225 to 648) 
3 0  days 353 (220 to 588) 411 (253 to 671) 
Olanges from baseLine to 4 8  72 h - 0 3 0 ( - 5 8 . 4 to 66.7) 135 (-71.7 to 37 3 )  
Olanges from baseLine to 3 0  days - 4 . 4 0  (-97.7 to 80)  17.3 ( - 5 4 . 0  to 121.9) 
Values are median (Ql to Q3). 
Abbreviations as in Tablet. 
p Value 
0.22 
0 5 8  
0 .028 
0 .067 
0 . 0 0 0 9  
TABLE 3 correlation o f  BaseUne KIM-1 With Other BaseUne Indices of  Renal Function• 
KM•1 CrHtinlne BUN Cystatin C eGFRt 
KIM 1 0.26 0.29 0.38 - 0 3 3
(p < 0.0001) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
Creatinine 0.26 0.69 0.70 -0 .89
(p < 0.0001) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
BUN 0.29 0.69 0.66 -0.74
(p < 0.0001) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
Cystatin C 0 3 8  0.70 0.66 -0.78
(p < 0.0001) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
eGFR• -0.33 - 0 . 8 9 -0 .74 -0.78
(p < 0.0001) (p < 0.0001) (p < 0.0001) (p < 0.0001) 
•Speannan oorrelation ooeffidems. teGFR e<timated by the 4-variable Mocification of Diet in Renal Disease  
on. 
eGFR estimated glomen,larfiltration rate; other abbreviations as in Table 1. 
RESULTS 
STUDY POPULATION. The median circulating KIM·l 
level at baseline was 375.4 pg/ml (IQR: 237.0 to 633.1 
pg/ml). Baseline characteristics stratified by baseline 
circulating KIM·l levels of this substudy cohort are 
provided in Table 1. Higher circulating KIM·l levels 
were associated with older age, prevalent female sex, 
prevalent diabetes mellitus, higher systolic blood 
pressure and lower heart rate, prevalent atrial fibril· 
lation, higher left ventricular ejection fraction, pre-
valent ischemic heart failure etiology, and lower 
mineralocorticoid receptor antagonist usage. In· 
creasing baseline KIM·l was also associated with 
baseline markers of worse renal function and neuro-
hormonal activation, including higher blood urea 
nitrogen, higher serum creatinine, and higher 
N-terminal prohormone brain natriuretic peptide 
levels. There was no association between baseline 
KIM·l and cardiac troponin-1 levels. 
SERIAL KIM•l LEVELS. Of the 874 patients with 
baseline KIM·l levels, 706 had KIM-1 levels drawn at 
48 to 72 h,  and 661 had KIM-1 levels drawn at 30 days. 
The median KIM-1 level at 48 to 72 h was 373.7 pg/ml 
(IQR: 220.3 to 640,5 pg/ml) and at 30 days was 
382.6 pg/ml (IQR: 236,5 to 638.o pg/ml). Table 2 
TABLE 4 Renal Outcomes Stratified by Baseline KIM-1 Level 
<278.3 
24 h b.aeatinine (µmoVl) 
24 h urine volume (ml) 
48 to 72 h b.cystatin C >03 mg/l 
(%) Dynamic renal function at 48 h 
(%) 
0.0 ( -8 .8  to 11.5) 
2,980 (1,900 to 4,170) 
17.9 
19.6 
demonstrates that there was a trend toward a 
larger increase in KIM·l levels from baseline to 48 
to 72 h when stratified by treatment (nesiritide vs. 
placebo) from randomization (13,5 pg/ml [IQR: 71.7 
to 37,3 pg/ml] vs. 0.30 pg/ml [IQR: 58.4 to 66.7 
pg/ml], respectively; p 0.067). However, this 
relationship became evident by 30 days, because 
the nesiritide arm demonstrated a greater increase 
in KIM·l levels compared with the placebo arm 
(17,3 pg/ml [IQR: 54.0 to 121.9 pg/ml] vs. 4.40 
pg/ml [IQR: 97,7 to 80.o pg/ml], respectively; 
p 0.0009), 
RELATIONSHIP OF KIM•l AND OTHER MEASURES 
OF RENAL FUNCTION AND ITS IMPACT ON RENAL 
OUTCOMES DURING HOSPITALIZATION. Baseline 
KIM-1 levels moderate! y correlated to other markers of 
renal function (Table 3), but were highly correlated to 
follow-upKIM-1 levelsat48to72h (Spearman p o.89; 
p < 0.0001) and 30 days (Spearman p o.82; 
p < 0.0001). The relationship between increasing 
baseline KIM·l levels and renal outcomes during 
treatment i s  shown in Table 4. Increasing baseline 
KIM· l was associated with a lesser 24·h urine volume 
(p 0.019), greater creatinine increase at 24 h (p 
0.048), more dynamic renal function at 48 h 
(defined as either an increase or decrease in serum 
creatinine o f  ;;eo,3 mg/dl; p 0.0008), and a greater 
incidence of  worsening renal function ( cystatin C 
>0.3 mg/1) by 48 to 72 h ( p  < 0.0001). Subjects who 
developed worsening renal function during decon· 
gestive therapy demonstrated higher plasma KIM·l 
levels at baseline and at 48 to 72 h (both p 
0.03), but not at 30 days (p 0.07) when compared 
with those who did not experience worsening renal 
function (Figure 1).  
ASSOCIATION OF BASELINE AND FOLLOW•UP KIM•l 
AND OUTCOMES. Kaplan-Meier estimates of survival 
at 180 days are shown in Figure 2 for baseline and 30· 
day KIM·l tertiles. There were 25 deaths (2.9%) by 30 
days and 100 deaths (11.6%) by 180 days. By 30 days, 
there were 101 deaths or recurrent heart failure 
Basollne KIM•1 (pg/ml) 
278.3-526.7 >526.7  p Value• 
0.048 
0.019 
0.044 
1.8 ( -8 .8  to 14.0) 
2,575 (1,700 to 3,500) 
25.9 
30.9 
1.8 ( -8 .8  to 17.7) 
2,550 (1,810 to 3,730) 
25.8 
33.8 0.0008 
Values are median (Ql to Q3) or%. •p value torn test of trend (Codlrane-Annitage trend test and Jondd1ee�·Terpstra trend tests). 
Abtw'e\"iations as in Table 1. 
hospitalizations (11.7%). The association between 
baseline, 48- to 72-h, and 30-day circulating KIM-1 
levels and dyspnea scores and clinical outcomes is 
shown in Table 5. In univariable analyses, higher 
baseline, 48- to 72-h, and 30-day log-transformed 
KIM-1 levels were only associated with 180-day mor-
tality (all p < 0.05), but not dyspnea or other clinical 
outcomes. After multivariable adjustment for all of the 
covariates in adjusted model 1, the association between 
log-transformed KIM-1 levels and 180-day mortality 
was weakly nonsigniﬁcant (p 0.053) when measured at 
baseline, but remained signiﬁcant when measured at 
48 to 72 h and 30 days (both p < 0.05). Dyspnea and the 
other clinical outcomes remained unassociated with 
log-transformed KIM-1. When the multivariable 
adjustment included blood urea nitrogen/creatinine 
(adjusted model 2), only 30-day log-transformed KIM-1 
levels were associ-ated with 180-day mortality (p 0.04). 
There was no interaction with 30-day KIM-1 levels and 
nesiri-tide treatment (p 0.89). Otherwise, none of the 
previous associations persisted and there remained no 
associations with log-transformed KIM-1 levels and 
dyspnea or other clinical outcomes. When stratifying 
by high or low KIM-1 levels (divided by median 
baseline values) and high or low cystatin C levels 
(divided by median baseline values), there were 
signiﬁcantly different Kaplan–Meier estimates of 180-
day survival (Figure 3) (p < 0.0001); none-theless, this 
seemed to be driven more by cystatin C than KIM-1. 
Individually, there was a nonsigniﬁcant 
trend toward lower  survival  for high versus 
low  KIM-1 (log-rank p 0.056) and a highly signiﬁcant 
lower survival for high versus low cystatin C (log-rank 
p < 0.0001).
DISCUSSION
There are several new ﬁndings from this analysis. 
First, overall circulating KIM-1 levels did not ﬂuc-
tuate to a great extent from ADHF to post-discharge 
follow-up (assuming a more stabilized state). Sec-
ond, circulating KIM-1 levels modestly track with 
other biomarkers of renal function (serum creatinine, 
blood urea nitrogen, and cystatin C), but were asso-
ciated with short-term adverse renal outcomes. Third, 
even though they track with long-term mor-tality in 
univariable comparison, circulating KIM-1 levels were 
not independently prognostic for either intermediate 
or long-term clinical outcomes when measured at 
either baseline or 48 to 72 h. Also, higher baseline 
cystatin C levels stratiﬁed mortality risk more than 
higher baseline KIM-1 levels. Last, subjects randomly 
assigned to nesiritide had higher
FIGURE  1  KIM-1 Levels at Different Time Points
KIM 1 levels at different time points according to the development of worsening renal 
function* by 72 h. *Deﬁned as a change in cystatin C >0.3 mg/l at 72 h from baseline. KIM 
kidney injury molecule; WRF worsening renal function.
levels of KIM-1 at 30 days than study subjects 
randomly assigned to placebo, although the clinical 
signiﬁcance of this observation is unclear because 
there was no interaction with 30-day KIM-1 levels and 
nesiritide treatment. Taken together, we con-clude 
that circulating KIM-1 levels yield limited incremental 
clinical or prognostic information dur-ing the 
management of ADHF independent of more 
traditional measures of renal function (creatinine and 
blood urea nitrogen). The only inconsistent ﬁnding 
was that 30-day follow-up KIM-1 levels were 
associated independently with 180-day mortality. 
This may reﬂect the relatively “stable” chronic na-
ture of 30-day clinical status in contrast with those 
measured during ADHF admission.
Worsening renal function in patients with ADHF is 
a well-described, strong predictor of adverse
outcomes (24–27). Consequently, successful treat-
ment of ADHF includes not only decongestion and 
symptom alleviation, but also maintaining or pre-
serving renal function. Clinical trials for novel 
therapies or treatments for both ADHF and chronic 
heart failure commonly have worsening renal 
function as a safety endpoint, or are aimed at pre-
serving renal function, although there has been 
increasing scrutiny over the reliability of renal 
indices as surrogate measures of cardiorenal dys-
function (28–31).
KIM-1 may be an early marker of cardiorenal syn-
drome (15), because it is highly expressed on the 
surface of injured tubule epithelial cells and transforms 
epithelial cells into phagocytic cells, which clear 
apoptotic and necrotic cells after acute tubular injury 
(11). As a result, urinary KIM-1 is a highly speciﬁc 
marker for acute tubular injury and is commonly 
increased in patients with heart failure (10,17). 
However, less is known about plasma levels of KIM-1. 
There are several reasons supporting its detection in 
the plasma after acute tubular injury: KIM-1 may be 
released directly into the interstitium through loss of 
tubular permeability and back-leak of contents into the 
circulation via breakdown of the microvascular 
architecture of the endothelial cells and basement 
membrane (32–34). Plasma KIM-1 levels correlate well 
with urinary KIM-1 levels and are associated with renal 
dysfunction (19). Consistent  with urinary KIM-1 
levels, our ﬁnding that plasma KIM-1 levels were only 
modestly correlated with other renal indices (Table 3) 
may imply other renal physiologic processes that are 
not reﬂected by more traditional metrics of renal 
function (16). Further-more, we observed that 
increased plasma KIM-1 at baseline is associated with 
decreased diuresis and a greater incidence of renal 
dysfunction (Table 4), and is higher in subjects who 
developed worsening renal function by 72 h (Figure 1), 
indicating that circul-ating KIM-1 levels do reﬂect some 
degree of renal insufﬁciency.
Although baseline urinary KIM-1 has been shown to 
yield incremental prognostic information to esti-mated 
glomerular ﬁltration in chronic heart failure, data from 
patients with ADHF have not shown the same 
association between elevated urinary KIM-1 and poor 
prognosis (16–18). Our current ﬁndings with circulating 
levels also demonstrated no incremental beneﬁt of 
KIM-1 levels when measured in plasma beyond more 
traditional markers of renal function in ADHF. There 
may be several potential explana-tions for this ﬁnding. 
First, altered central or renal hemodynamics as a result 
of increased venous con-gestion and/or decreased 
cardiac output may affect
FIGURE  2  Kaplan-Meier Estimates of 180-Day Survival According 
to Baseline and 30-Day KIM-1 Levels
Kaplan Meier estimates of 180 day survival according to (A) baseline KIM 1 levels
(tertile 1, <278.3 pg/ml; tertile 2, 278.3 to 526.7 pg/ml; and tertile 3, >526.7 pg/ml) and 
(B) 30 day KIM 1 levels (tertile 1, <282.0 pg/ml; tertile 2, 282.0 to 530.1 pg/ml; and 
tertile 3, >530.1 pg/ml). Abbreviations as in Figure 1.
TABLE 5 KIM-1 Levels and Intermediate- and Long-Term Outcomes 
Unadjusted• Adjusted Model 1t Adjusted Model 2* 
Endpoint OR/HR p Value OR/HR p Value OR/HR pValue 
BaseLine KIM 1 levels 
1.15 D55 1.10 D.73 D.88 D.68 
1.06 D.63 1.04 D.73 D.90 D.44 
1.28 0.04 1.30 0.053 1.12 0.44 
0.91 030 0.90 0.38 0.91 0.45 
1.04 0.75 1.03 0.86 1.07 0.68 
Death at 30 days 
Death/rehospitalization at 30 days 
Death at 18D days 
Improved dyspnea at 6 h 
Improved dyspnea at 24 h 
Death or worsening HF pre discharge 1.40 0.07 1.37 0.11 1.07 0.75 
48 to 72 h follow up KIM 1 levels 
1.17 056 1.08 0.81 0.82 054 
1.10 0.47 1.06 0.65 0.88 034 
1.42 0.006 1.46 O.Ol 1.23 0.21 
0.93 0.47 0.93 0.57 0.91 052 
0.91 050 0.99 0.94 1.07 0.70 
Death at 30 days 
Death/rehospitalization at 30 days 
Death at 180 days 
Improved dyspnea at 6 h Improved 
dyspnea at 24 h 
Death or worsening HF pre discharge 1.19 039 1.07 0.76 0.75 0.25 
30 day KIM 1 levels 
Death at 180 days 1.60 0.002 1.75 0.002 1.49 0.04 
'U\adjusted, ooly log-transformed KIM-1. tAdjusted irodel 1, log-transformed KIM·l adjusted with covariates deri',@(j from the ori nal ASCEND-HF population 
exducing BUN/aeatiline. *Adjusted irodel 2. log-transformed KIM·l adjusted with covariates derived from the origilal ASCEND-HF pop,bticn indudilg BUN/aeatiline. 
HF heart failure; HR hazard ratio; OR odds ratio; other abbreviations as in Table I. 
glomerular filtration more than tubular function in 
the kidneys. Second, although KIM·l is a sensitive 
marker for tubular injury resulting from nephrotoxic 
medications, the degree of tubular injury may not be 
as severe during ADHF, as indicated by 
previous studies on urinary neutrophil gelatinase-
associated lipocalin, which is another marker of 
renal tubular damage (35,36). 
There was a trend of higher KIM -1 in the nesiritide 
versus placebo groups, but there was a limited 
impact on clinical outcomes between treatment 
groups, and there was no interaction with 30-day 
KIM·l levels and nesiritide treatment. Therefore, 
using a surro-gate marker of tubular injury 
without assessing "hard" adverse outcomes remains 
a challenge. 
STUDY LIMITATIONS. The results of this study 
must be interpreted in light of various limitations 
inherent to its design. First, the absence of overlap 
between creatinine, cystatin C, and blood urea 
nitrogen values in conjunction with the KIM·l draws 
(48 to 72 hand 30 days of blood sampled and 
analyzed in the core laboratory versus clinically 
collected creatinine and blood urea nitrogen levels 
at baseline, 24 h, and at the end of treatment) and 
the absence of available urine output data past 24 h, 
limit our ability to assess cardiorenal outcomes 
during the remainder of hos-pitalization. Second, 
there was a paucity of data to assess the 
additional contribution of other heart 
failure pharmacotherapies on the incidence 
of renal insufficiency or clinical outcomes. 
Finally, although nesiritide use was associated 
with higher follow-up KIM-1 levels, caution should 
be used in interpreting these results, because this 
study was 
FIGURE 3 Kaplan-Meler Estimates of 180-Day Survival According to 
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trend toward lower survival for high versus low KIM 1 (log rank p 0.056) and a 
highly significant lower survival for high versus low cystatin C (log rank p < O.OOOI). 
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not appropriately powered to demonstrate such a 
difference. Regardless, with carefully adjudicated 
outcomes, our analysis suggests that there is little 
role for measuring plasma KIM-1 and predicting 
adverse clinical outcomes in ADHF, but does 
provide insight into renal tubular damage in heart 
failure and its prognostic implications.
CONCLUSIONS
In our study cohort, circulating KIM-1 at baseline and 
during hospitalization was not associated with 
adverse clinical outcomes in ADHF after adjusting for 
standard indices of kidney function. Nesiritide use 
may be associated with a greater rise in 
circulating KIM-1 levels, although its use did not 
correlate with adverse clinical outcomes.
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